Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis

11. März 2019 aktualisiert von: Lycera Corp.

A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis

The purpose of the study is to evaluate the efficacy and safety of LYC-30937-EC given orally once daily in subjects with active ulcerative colitis (UC) defined as a total Mayo score (TMS) of 4-11 inclusive, with an endoscopic score of ≥ 2 and a rectal bleeding score of ≥ 1 at screening.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Approximately 120 subjects will be randomized to receive either enteric-coated (EC) LYC-30937-EC 25 mg PO once daily (QD) or matching placebo PO QD for the duration of 8 weeks. Randomization will be stratified based on previous exposure to anti-tumor necrosis factor (TNF) agents such that at least 50% of the randomized subjects will be anti-TNF naïve .

The study will consist of 3 phases:

  • screening phase: up to 4 weeks
  • double-blind placebo-controlled phase treatment: 8 weeks
  • post-treatment follow-up: 2 weeks

Eligible subjects will be randomized at Week 0 (Study Day 1) to either LYC-30937-EC 25 mg or placebo. Screening will occur from Study Days -28 to -1. Randomization and first dosing will occur at Week 0/Study Day 1. Double-blind study visits will occur at Weeks 2, 4, and 8, with the last dose at Week 8/Study Day 57. Subjects will return at Week 10 for a post-treatment safety follow-up visit.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

124

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Kanada
    • British Columbia
      • Victoria, British Columbia, Kanada, V8V 3M9
        • Lycera Investigational Site
    • Ontario
      • Toronto, Ontario, Kanada, M5G 1X5
        • Lycera Investigational Site
  • Niederlande
      • Amsterdam, Niederlande, 1081 HZ
        • Lycera Investigational Site
      • Rotterdam, Niederlande, 3015 CE
        • Lycera Investigational Site
  • Polen
      • Bydgoszcz, Polen, 85-168
        • Lycera Investigational Site
      • Bydgoszcz, Polen, 85-681
        • Lycera Investigational Site
      • Katowice, Polen, 40-211
        • Lycera Investigational Site
      • Katowice, Polen, 40-659
        • Lycera Investigational Site
      • Katowice, Polen, 40-752
        • Lycera Investigational Site
      • Kielce, Polen, 25 364
        • Lycera Investigational Site
      • Krakow, Polen, 30-415
        • Lycera Investigational Site
      • Krakow, Polen, 31-009
        • Lycera Investigational Site
      • Ksawerów, Polen, 95-054
        • Lycera Investigational Site
      • Lublin, Polen, 20-362
        • Lycera Investigational Site
      • Lublin, Polen, 20-008
        • Lycera Investigational Site
      • Nowa Sól, Polen, 67-100
        • Lycera Investigational Site
      • Piaseczno, Polen, 05-500
        • Lycera Investigational Site
      • Poznan, Polen, 61-113
        • Lycera Investigational Site
      • Skierniewice, Polen, 96-100
        • Lycera Investigational Site
      • Sopot, Polen, 81-756
        • Lycera Investigational Site
      • Staszów, Polen, 28-200
        • Lycera Investigational Site
      • Szczecin, Polen, 71-270
        • Lycera Investigational Site
      • Warszawa, Polen, 02-507
        • Lycera Investigational Site
      • Warszawa, Polen, 04-749
        • Lycera Investigational Site
      • Wloclawek, Polen, 87-800
        • Lycera Investigational Site
      • Wroclaw, Polen, 50-053
        • Lycera Investigational Site
      • Wroclaw, Polen, 54-144
        • Lycera Investigational Site
      • Wrocław, Polen, 53-333
        • Lycera Investigational Site
      • Wrocław, Polen, 50-449
        • Lycera Investigational Site
      • Łódź, Polen, 93-034
        • Lycera Investigational Site
  • Serbien
      • Belgrade, Serbien, 11000
        • Lycera Investigational Site
      • Belgrade, Serbien, 11080
        • Lycera Investigational Site
      • Kragujevac, Serbien, 34000
        • Lycera Investigational Site
      • Niš, Serbien, 18000
        • Lycera Investigational Site
      • Subotica, Serbien, 24000
        • Lycera Investigational Site
      • Zrenjanin, Serbien, 23000
        • Lycera Investigational Site
  • Tschechien
      • Ostrava, Tschechien, 722 00
        • Lycera Investigational Site
      • Praha, Tschechien, 130 00
        • Lycera Investigational Site
      • Praha 3, Tschechien, 130 00
        • Lycera Investigational Site
      • Slany, Tschechien, 274 01
        • Lycera Investigational Site
      • Usti nad Labem, Tschechien, 401 13
        • Lycera Investigational Site
  • Ungarn
      • Budapest, Ungarn, 1088
        • Lycera Investigational Site
      • Budapest, Ungarn, 1125
        • Lycera Investigational Site
      • Debrecen, Ungarn, 4031
        • Lycera Investigational Site
      • Debrecen, Ungarn, 4032
        • Lycera Investigational Site
      • Hatvan, Ungarn, 3000
        • Lycera Investigational Site
  • Vereinigte Staaten
    • Arkansas
      • Little Rock, Arkansas, Vereinigte Staaten, 72212
        • Lycera Investigational Site
    • California
      • Long Beach, California, Vereinigte Staaten, 90822
        • Lycera Investigational Site
      • Mission Hills, California, Vereinigte Staaten, 91345
        • Lycera Investigational Site
      • Rialto, California, Vereinigte Staaten, 92377
        • Lycera Investigational Site
    • Florida
      • Hollywood, Florida, Vereinigte Staaten, 33021
        • Lycera Investigational Site
      • Miami, Florida, Vereinigte Staaten, 33176
        • Lycera Investigational Site
    • Georgia
      • Decatur, Georgia, Vereinigte Staaten, 30033
        • Lycera Investigational Site
      • Marietta, Georgia, Vereinigte Staaten, 30060
        • Lycera Investigational Site
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60637
        • Lycera Investigational Site
    • Kentucky
      • Louisville, Kentucky, Vereinigte Staaten, 40202
        • Lycera Investigational Site
    • Louisiana
      • Baton Rouge, Louisiana, Vereinigte Staaten, 70809
        • Lycera Investigational Site
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48109
        • Lycera Investigational Site
    • New York
      • Bronx, New York, Vereinigte Staaten, 10461
        • Lycera Investigational Site
      • Brooklyn, New York, Vereinigte Staaten, 11230
        • Lycera Investigational Site
      • New York, New York, Vereinigte Staaten, 10024
        • Lycera Investigational Site
    • North Carolina
      • Greenville, North Carolina, Vereinigte Staaten, 27834
        • Lycera Investigational Site
    • Pennsylvania
      • Flourtown, Pennsylvania, Vereinigte Staaten, 19031
        • Lycera Investigational Site
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Lycera Investigational Site
      • Sayre, Pennsylvania, Vereinigte Staaten, 18840
        • Lycera Investigational Site
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37212
        • Lycera Investigational Site
      • Union City, Tennessee, Vereinigte Staaten, 38261
        • Lycera Investigational Site
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • Lycera Investigational Site
      • Houston, Texas, Vereinigte Staaten, 76092
        • Lycera Investigational Site.
      • Houston, Texas, Vereinigte Staaten, 77004
        • Lycera Investigational Sites
      • Houston, Texas, Vereinigte Staaten, 77004
        • Lycera Investigational Site
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • Lycera Investigational Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Clinical UC diagnosis ≥ 6 months prior to screening with minimum disease extent of ≥ 15cm from anal verge.
  • Active UC defined as a TMS of 4-11 (inclusive) with endoscopic subscore of ≥ 2 and rectal bleeding subscore of ≥ 1 at screening.
  • Females of childbearing potential must have a negative pregnancy test at screening and baseline visits and must agree to use acceptable methods of birth control while in the trial and for 30 days after taking the last dose of study drug.
  • May be currently receiving treatment with oral aminosalicylates (ASA) for ≥ 6 weeks at a stable dose for ≥ 3 weeks prior to the screening screening endoscopy and/or thiopurine at a stable dose ≥ 8 weeks prior to the screening endoscopy and/or prednisone (dose 20 mg daily) or equivalent for ≥ 4 weeks and receiving stable dose for ≥ 2 weeks prior to screening endoscopy
  • able to provide written informed consent and be compliant with study procedures.

Exclusion Criteria:

  • History of Crohn's disease (CD) or indeterminate colitis or the presence or history of fistula consistent with CD.
  • Presence of colon polyps.
  • Severe extensive disease that in the investigators discretion is likely to require colonic surgery during the 8 week double-blind portion of the trial (eg, fulminant colitis, toxic megacolon, bowel perforation, evidence of acute abdomen).
  • History of alcohol or drug abuse within 1 year of randomization.
  • History of cancer including solid tumors and hematological malignancies (except basal cell and in situ squamous cell carcinomas of the skin that have been adequately treated with no recurrence for ≥ 1 year prior to screening.
  • History or currently active primary or secondary immunodeficiency.
  • Clinically relevant hepatic, neurologic, pulmonary, ophthalmological, gastrointestinal, endocrine, psychiatric, or other major systemic disease making implementation of the study difficult or that would put the subject at risk by participating in the study
  • Positive test for Clostridium difficile or positive stool culture for enteric pathogens or presence of ova or parasites at screening.
  • Liver function tests > 1.5 x upper limit of normal (ULN) or direct bilirubin > 1.5 x ULN
  • Hemoglobin < 8.5 g/dl
  • Neutrophils < 1500/mm3
  • White blood cell (WBC) count < 3000/mm3
  • Platelets < 80000 mm3
  • International normalized ratio (INR) > 1.5
  • Treatment with an immunosuppressant agent within 8 weeks of screening.
  • Previous exposure to ≥ 2 approved or investigational biologic agents to treat UC.
  • History of UC treatment with a biologic agent within 12 weeks of screening.
  • Treatment with rectal steroids within 2 weeks of screening.
  • Treatment with an investigational agent within 30 days of screening.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: LYC-30937-EC 25 mg PO QD
LYC-30937-EC 25 mg by mouth once daily for 8 weeks
Arzneimittel: LYC-30937-EC
Placebo-Komparator: Placebo PO QD
Matching placebo by mouth once daily for 8 weeks
Arzneimittel: Placebo

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Subjects Who Achieve Clinical Remission at Week 8 Using Modified Mayo Score.
Zeitfenster: 8 weeks

The modified Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 9 points and consists of 3 subscores (stool frequency, rectal bleeding, endoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally.

Clinical remission on the modified Mayo score was defined as a Mayo stool frequency subscore of ≤ 1, Mayo rectal bleeding subscore of 0 and a Mayo endoscopy subscore of ≤ 1.
8 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Subjects Who Achieve Clinical Remission at Week 8 Using the Total Mayo Score.
Zeitfenster: 8 weeks

The total Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, endoscopy, physicians global assessment), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally.

Clinical remission on the total Mayo Score is defined as a total Mayo score of ≤ 2, with no individual subscore > 1.
8 weeks
Number of Subjects With a Clinical Response on the Modified Mayo Score at Week 8.
Zeitfenster: 8 weeks

The modified Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 9 points and consists of 3 subscores (stool frequency, rectal bleeding, endoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally.

Clinical response on the modified Mayo score at Week 8 was defined as a reduction from the baseline modified Mayo score of ≥ 2 points and ≥ 25%, and a decrease from baseline in rectal bleeding score of ≥ 1 point or absolute rectal bleeding score of ≤ 1 point.
8 weeks
Number of Subjects With a Clinical Response on the Total Mayo Score at Week 8.
Zeitfenster: 8 weeks

The total Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, endoscopy, physicians global assessment), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally.

Clinical response on the total Mayo score at Week 8 was defined as a reduction from baseline total Mayo score of ≥ 3 points and ≥ 30%, and a decrease from baseline in rectal bleeding score of ≥ 1 point or absolute rectal bleeding score of ≤ 1 point.
8 weeks
Percent Change From Baseline to Week 8 in Fecal Calprotectin in Subjects With Baseline Fecal Calprotectin ≥ 250 µg/g
Zeitfenster: Baseline to Week 8
Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation.
Baseline to Week 8
Percent Change From Baseline in Total Mayo Score at Week 8.
Zeitfenster: Baseline to Week 8

Analyzes the change in total Mayo score score between baseline and Week 8 for all randomized subjects who had total Mayo score scores at both baseline and Week 8.

The total Mayo score is a tool designed to measure disease activity for ulcerative colitis. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, endoscopy, physicians global assessment), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopy scoring was performed centrally.
Baseline to Week 8

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Subjects With Type of Adverse Events (AEs) Serious Adverse Events (SAEs) and AEs That Led to Discontinuation of Treatment.
Zeitfenster: 10 weeks
Adverse events (AEs) were collected from the time a subject signed the informed consent. Treatment-emergent adverse events (TEAEs) are AEs occurring or worsening after the first dose of study drug (LYC-30937-EC 25 mg or placebo). Adverse event severity was assessed by the Investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03, with grading as follows: Grade 1 = mild (asymptomatic or mild symptoms), Grade 2 = moderate (minimal, local intervention, or noninvasive intervention indicated); Grade 3 = severe (or medically significant but not life-threatening); Grade 4 = life-threatening; Grade 5 = death.
10 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Lycera Corp.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Juli 2016

Primärer Abschluss (Tatsächlich)

1. Mai 2018

Studienabschluss (Tatsächlich)

1. Mai 2018

Studienanmeldedaten

Zuerst eingereicht

3. Mai 2016

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. Mai 2016

Zuerst gepostet (Schätzen)

5. Mai 2016

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

2. April 2019

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. März 2019

Zuletzt verifiziert

1. März 2019

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • LYC-30937-2001
  • 2016-000518-31 (EudraCT-Nummer)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Kolitis, Geschwür

Klinische Studien zur Placebo

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Georgia

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren